Information about Bevacizumab
Generic Name : Bevacizumab
Pronunciation : be va siz' yoo mab
Latest prescription information about Bevacizumab. Learn how to pronounce the drug's name, its indications, dosage, how to take, when to take, when not to take, side effects, special precautions, warnings and its storage instructions . Also listed are the International and Indian trade name(s) of the drug and its price list.
ICD Code : Y43.3
Therapeutic Classification : Chemotherapy
Trade Names/Brand Names of Bevacizumab
Other Name(s) of Bevacizumab
Overview of Bevacizumab
Bevacizumab inhibits a protein named Vascular endothelial growth factor (VEGF).
VEGF helps for promoting blood vessel growth, providing nutrition for cancer cells. By inhibiting VEGF, bevacizumab inhibits the growth of cancer cells.
Why is Bevacizumab Prescribed? (Indications)
This medication is used to treat certain types of advanced lung cancer. It is also used to treat certain types of brain, breast, kidney, colon, or rectal cancer along with other cancer medicines. Bevacizumab is indicated for treating colorectal cancer that spreads to other areas along with intravenous fluorouracil-based chemotherapy.
Certain types of liver cancer
Certain types of renal(kidney) cell cancer, cervical, fallopian tube, ovarian cancers, Glioblastoma.
When should Bevacizumab not be taken? (Contraindications)
Contraindicated in patients with hole in stomach or intestine, wound, and hypersensitivity.
What is the dosage of Bevacizumab?
Metastatic Carcinoma of the Colon or Rectum - Adults
IV infusion 5 or 10 mg/kg every 14 days in combination with IV 5-fluorouracilοΏ½based chemotherapy.
The recommended dosage is 5 mg/kg every 14 days when administered with irinotecan/5-fluorouracil/leucovorin, and 10 mg/kg every 14 days when administered with 5-fluorouracil/leucovorin/oxaliplatin.
How should Bevacizumab be taken?
This medication is available in the form of injection, administered by health care providers, intravenously.
It is taken in the dose of 5-10 mg/kg body weight every 2 weeks with other chemotherapeutic agents for colorectal cancer
For lung cancer: 15 mg/kg every 3 weeks with carboplatin and paclitaxel
10 mg/kg every 2 weeks for renal cancer
The recommended dosage is 10 mg/kg intravenously every 2 weeks for glioblastoma.
15 mg/kg every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan for Stage III or IV ovarian, fallopian tube or peritoneal cancer after surgical resection.
What are the warnings and precautions for Bevacizumab?
• It may reduce the number of clot-forming cells (platelets) in your blood. Avoid injuries.
Caution should be exercised in patients with history of cancer and heart disease, congestive heart failure, high blood pressure, during pregnancy and lactation.
What are the side effects of Bevacizumab?
• Gastrointestinal: Changes in taste, constipation, diarrhea, increased thirst, indigestion, loss of appetite, mouth pain or sores, nausea, vomiting, black, tarry stools and dry mouth.
• Central Nervous System: Dizziness, tiredness and headache.
• Skin: Dry skin, hair loss, swelling, or redness at the injection site, rash, hives, itching and swelling of the mouth, face, lips, or tongue.
• Eye and ENT: Nosebleed, stuffy or runny nose and voice changes.
• Heart: Difficulty breathing, tightness in the chest, congestive heart failure, calf pain or tenderness and chest pain.
• Miscellaneous: Muscle pain, sluggishness, weakness and weight loss.
What are the other precautions for Bevacizumab?
Caution is required in patients with:
Gastrointestinal perforations and Fistula
Posterior Reversible Encephalopathy Syndrome (PRES)
Renal Injury and Proteinuria
Pregnant and lactating women
What are the Drug Interactions of Bevacizumab?
Bevacizumab can interact with the following drugs in various extents:
What are the storage conditions for Bevacizumab?
It is normally handled and stored by healthcare providers.
Last Updated : 20-09-2021